Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARIOT: Copanlisib + Degarelix in High-Risk Localized Prostate Cancer
NCT06218667Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of copanlisib in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Jan 2024; status: withdrawn.
02
Drugs
copanlisib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06218667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218667.